Biotechnology & Drugs Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotechnology & Drugs

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: 2MAR$ who wrote (210)	11/25/2003 9:57:17 PM
From: 2MAR$	Read Replies (1) of 232

Study Shows Success in a New Use of BIIB/DNA's ---->Rituxan Wednesday November 12, 6:27 pm ET By Adam Feuerstein, Senior Writer BIIB Chart : stockcharts.com[h,a]waclyyay[pb50!b200][vc60][iUc20!La12,26,9]&pref=G Updated from Nov. 12 A study investigating long term, or "maintenance" use of the cancer drug Rituxan in patients with low-grade, or indolent non-Hodgkin's lymphoma was halted early due to positive efficacy results, TheStreet.com has learned. The news is a win for Rituxan's co-marketers Biogen Idec (BIIB - News)and Genentech (NYSE:DNA - News) because the study has the potential to re-energize sales at a time when Rituxan sales growth was slowing. Rituxan sales should exceed $1.5 billion this year, making it the most successful biotech-derived cancer drug ever, but market share already approaches 70%. Biogen and Idec

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next